AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q83499

Application No.: 10/507,486

REMARKS

In the present Amendment, independent claim 7 has been amended. With regard to the aryl group having at least one iodine atom as a substituent represented by Ar¹¹ and Ar¹², the claim has been amended to recite that the aryl group is selected from an anthracenyl group, a naphthalenyl group, and a phenyl group. Section 112 support for this amendment may be found, for example, at pages 11 and 12 of the specification.

Also, the definition of the divalent bridging group represented by L¹¹ and L¹² has been amended to recite that the group (whose main chain contains 6 or more carbon atoms) is selected from the bridging groups described at page 18, lines 11-16 and the alkenyl bridging group shown at the top of page 8 of the Office Action. The latter group finds support, for example, in compound (1B-8) at page 26 of the specification.

Still further, the definition of R¹¹ has been amended. Claim 7 recited that R¹¹ represents a hydrogen atom or an alkyl group having two or more carbon atoms and having a functional group containing at least one heteroatom as a substituent. The claim as amended recites that the R¹¹ alkyl group contains 2 to 20 carbon atoms. Also, a Markush group of functional groups containing at least one heteroatom has been added, based on the description at page 20, line 15 to page 21, line 6 of the specification. See particularly page 21, lines 1-4.

New claim 33 has been added. Claim 33 depends from claim 7, and recites that R¹¹ is a hydrogen atom or an alkyl group containing 2 to 20 carbon atoms that is substituted with a quaternary ammonium group. Support for this claim may be seen, for example, in compounds (1B-1) to (1B-9) at pages 25-26 of the specification.

No new matter has been added and entry of the Amendment is respectfully requested.

In regard to the restriction requirement, Applicants affirm their election of Group II, claims 7-10.

Claims 1-6 and 11-32 are withdrawn from consideration.

At page 4 of the Action, claims 7-10 are rejected under 35 U.S.C. § 112, first paragraph, on the ground that the specification, while being enabling for anthracenyl, naphthalenyl, and phenyl, does not reasonably provide enablement for all aryl groups.

As noted above, independent claim 7 has been amended to recite aryl groups for Ar^{11} and Ar^{12} in Markush form. The Amendment is believed to address the Examiner's concern.

Reconsideration and withdrawal of this §112, first paragraph, rejection of claims 7-10 are respectfully requested.

At page 6 of the Action, claims 7-10 are rejected under 35 U.S.C. § 112, first paragraph, on the ground that the specification, while being enabling for the L¹¹ and L¹² groups listed on page 18, lines 11-16, does not reasonably provide enablement for all divalent bridging groups of which the main chain contains 6 or more carbon atoms.

As discussed, claim 7 has been amended to recite, in Markush form, divalent bridging groups for L^{11} and L^{12} .

In view of the above, the Examiner is kindly requested to reconsider and withdraw this §112, first paragraph, rejection of claims 7-10.

At page 8 of the Action, claims 7-10 are rejected under 35 U.S.C. § 112, first paragraph, on the ground that the specification, while being enabling for the functional groups recited in the Action, does not reasonably provide enablement for all functional groups containing at least one heteroatom as a substituent.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q83499

Application No.: 10/507,486

Applicants in the present amendment have amended the definition of R¹¹ to recite in

Markush form functional groups containing at least one heteroatom. Section 112 support for the

amendment is as discussed above, and the claim as amended is believed to address the

Examiner's concern.

Reconsideration and withdrawal of this §112, first paragraph, rejection of claims 7-10 are

kindly requested.

Allowance is respectfully requested. If any points remain in issue which the Examiner

feels may be best resolved through a personal or telephone interview, the Examiner is kindly

requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 32,765

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: May 21, 2007

12